Literature DB >> 3030642

Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease.

J F Metcalf, J Koga, S Chatterjee, R J Whitley.   

Abstract

The effects of passive immunization with specific monoclonal antibodies against herpes simplex virus glycoproteins gB, gC, gD, and gE on the course of herpetic keratitis, survival and the establishment of latency in an outbred mouse model are described. A total of nine monoclonal antibodies were tested in these experiments. Passive immunization at 24 or 48 hours post-inoculation had little effect on the severity of the initial epithelial infection of the cornea, but blocked dissemination of the virus to the central nervous system and periocular tissues and prevented development of blepharitis, iritis and stromal keratitis. Additional studies are needed to characterize these monoclonal antibodies in greater detail, and to define the mechanism of these protective effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3030642     DOI: 10.3109/02713688709020086

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  17 in total

1.  Suppression of transcription factor early growth response 1 reduces herpes simplex virus 1-induced corneal disease in mice.

Authors:  Hui-Wen Yao; Shih-Heng Chen; Ching Li; Yuk-Ying Tung; Shun-Hua Chen
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

2.  Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.

Authors:  Kening Wang; Georgia D Tomaras; Sinthujan Jegaskanda; M Anthony Moody; Hua-Xin Liao; Kyle N Goodman; Phillip W Berman; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayapan; Jaranit Kaewkungwal; Barton F Haynes; Jeffrey I Cohen
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

3.  Specific antibody production in herpes keratitis: intraocular inflammation and corneal neovascularisation as predicting factors.

Authors:  Pierre-Yves Robert; Anja Liekfeld; Sylvia Metzner; Sylvie Ranger-Rogez; Jean-Paul Adenis; François Denis; Christian Hartmann; Uwe Pleyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-26       Impact factor: 3.117

4.  Diffusion of immunoglobulins into rabbit cornea after subconjunctival injection: experimental demonstration and mathematical model.

Authors:  R Osusky; A Morell; P Imbach; P G Lerch
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-02       Impact factor: 3.117

5.  Murine herpes simplex virus keratitis is accentuated by CD4+, V beta 8.2+ Th2 T cells.

Authors:  C S Foster; A Rodriguez Garcia; M Pedroza-Seres; A Berra; A Heiligenhaus; S Soukiasian; S Jayaraman
Journal:  Trans Am Ophthalmol Soc       Date:  1993

6.  Kinetics of immune cell infiltration in vaccinia virus keratitis.

Authors:  Sharon Altmann; Megan Toomey; Brittany Nesbit; Kim McIntyre; Jill Covert; Richard Redd Dubielzig; Gary Leatherberry; Elizabeth Adkins; Christopher J Murphy; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-07       Impact factor: 4.799

7.  Humanized antibodies for antiviral therapy.

Authors:  M S Co; M Deschamps; R J Whitley; C Queen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

8.  Anti-glycoprotein D monoclonal antibody protects against herpes simplex virus type 1-induced diseases in mice functionally depleted of selected T-cell subsets or asialo GM1+ cells.

Authors:  H F Staats; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

9.  Neutrophil-mediated suppression of virus replication after herpes simplex virus type 1 infection of the murine cornea.

Authors:  T M Tumpey; S H Chen; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Protective antibody therapy is associated with reduced chemokine transcripts in herpes simplex virus type 1 corneal infection.

Authors:  Y H Su; X T Yan; J E Oakes; R N Lausch
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.